Introduction
============

Congenital hypothyroidism (CH) is the most common congenital endocrine disorder with an incidence of approximately 1/2,000-4,000 newborns ([@b1-mmr-22-01-297]). According to the locations of lesions, CH can be classified into primary, central and peripheral hypothyroidism ([@b1-mmr-22-01-297],[@b2-mmr-22-01-297]). Primary hypothyroidism accounts for \>95% of CH cases ([@b3-mmr-22-01-297]), the majority of which (80-85%) are caused by alterations occurring during gland organogenesis. These alterations result in thyroid dysgenesis (TD) ([@b1-mmr-22-01-297],[@b4-mmr-22-01-297]). The remaining cases (15-20%) are attributed to inborn defects in thyroid hormone synthesis. These defects are collectively known as dyshormonogenesis (DH) and are generally characterized by either goiter or normal thyroid glands ([@b1-mmr-22-01-297],[@b5-mmr-22-01-297],[@b6-mmr-22-01-297]). By contrast, central and peripheral hypothyroidisms are rare disorders.

Considerable progress has been made in the understanding of CH pathophysiology. Although most cases of CH occur sporadically, approximately 20% are familial and caused by genetic abnormalities ([@b1-mmr-22-01-297],[@b2-mmr-22-01-297]). For TD, approximately 2--5% of reported cases have a genetic origin. Genes associated with TD (*PAX8, NKX2-1*/*TTF-1, FOXE1*/*TTF-2, NKX2-5* and *TSHR*) play important roles during thyroid morphogenesis ([@b1-mmr-22-01-297],[@b4-mmr-22-01-297]). The molecular mechanism of DH has been well characterized and most of the cases have been linked to mutations in genes involved in thyroid hormone synthesis (*TG, TPO, DUOX1/2, DUOXA2, SLC5A5, SLC26A4*/*PDS, IYD*/*DEHAL1* and *SECISBP2*). These mutations are usually transmitted in an autosomal recessive mode ([@b1-mmr-22-01-297],[@b5-mmr-22-01-297],[@b7-mmr-22-01-297]). The underlying molecular basis of central and peripheral hypothyroidism remains unclear, although genetic ascertainment is possible in some cases ([@b1-mmr-22-01-297],[@b6-mmr-22-01-297]). Mutations have been reported in genes controlling the biosynthetic pathway of thyroid stimulating hormone (*TSH*; *TSHB, TRHR* and *IGSF1*), pituitary development (*POU1F1, PROP1, HESX1, LHX3, LHX4* and *SOX3*) ([@b1-mmr-22-01-297],[@b6-mmr-22-01-297]) and thyroid hormone transport or action (*SLC16A2*/*MCT8, THRB* and *THRA*) ([@b1-mmr-22-01-297]). Other genes (*FOXI1, GLIS3, UBR1* and *ZNF252P*) have been reported in cases with syndromic hypothyroidism or transient CH and may be involved in CH ([@b8-mmr-22-01-297]--[@b13-mmr-22-01-297]). These causative genes and their functions are described in [Table SI](#SD2-mmr-22-01-297){ref-type="supplementary-material"}.

Although CH can be classified as a disease with a strong genetic component, many issues remain unresolved. One is the commonly observed variable phenotype-genotype correlations in patients ([@b5-mmr-22-01-297],[@b14-mmr-22-01-297]). This phenotypic or genetic heterogeneity suggests that mono- and polygenic factors and environmental modulators have roles in the determination of disease severity ([@b4-mmr-22-01-297],[@b5-mmr-22-01-297]). Some cases have oligogenic mutations apart from single-gene mutations and demonstrate heterogeneous phenotypes to those carrying monogenic mutations ([@b15-mmr-22-01-297]--[@b17-mmr-22-01-297]). These cases may not be inherited in a monogenic manner; that is, a digenic or oligogenic inheritance may be considered, or mutations may occur, acting as a genetic modifiers ([@b18-mmr-22-01-297],[@b19-mmr-22-01-297]). However, no definite evidence is able to prove this phenomenon. Next-generation sequencing (NGS) can be used for the simultaneous sequencing of multiple genes in a single sample and is useful in determining mutations in multiple genes that are potentially associated with diseases ([@b20-mmr-22-01-297],[@b21-mmr-22-01-297]). Thus, NGS is a powerful tool for unraveling the pathogeneses of complex diseases. Given the genetic complexity and heterogeneity of CH, all known causative genes should be comprehensively screened for mutations for the proper understanding of CH pathogenesis.

According to the largest national newborn screening program between 2013 and 2015, the total incidence rate of CH in China is 4.13 per 10,000 live births, which is higher than the worldwide level ([@b22-mmr-22-01-297],[@b23-mmr-22-01-297]). To date, the comprehensive screening of the known pathogenic genes in Chinese patients is limited. The present study designed a targeted NGS panel including 29 CH-related genes to screen mutations in a Chinese patient cohort from Shaanxi Province, China.

Materials and methods
=====================

### Subjects

A total of 43 patients with CH from 42 families were recruited in Xi\'an Children\'s Hospital and Chang\'an Hospital, Xi\'an, China, between October 2015 and August 2016. The age of the patients at the time of the study was 3 months-13 years. The inclusion criteria were: Positive neonatal screening with a diagnosis of CH confirmed by serum thyroid function tests at 2--4 weeks of age. Neonatal screening for CH was taken from 72 h to 7 days after birth. Blood samples were collected from the heel to determine TSH levels by using time-resolved fluorescence assay (PerkinElmer, Inc.). Newborns (2-4 weeks) with TSH levels of \>10 µIU/ml were recalled for the re-examination of serum TSH and FT4 levels by electrochemiluminescence assay (Cobas 6000, Roche Diagnostics). CH diagnosis was based on elevated serum TSH (\>7.5 µIU/ml; normal: 0.27--3.20 µIU/ml) and decreased FT4 levels (0.5--3.1 pmol/l; normal: 12--22 pmol/l). Levothyroxine (L-T4) treatment was initiated when elevated TSH level (\>10 µIU/ml) was confirmed. All the patients had a phenotypical classification by thyroid ultrasonography performed during the neonatal period prior to treatment. Additional information on the possible existence of thyroid disease in family members was collected in all cases. The neonatal screening, diagnosis and follow-up of each patient were conducted in the same hospital: Xi\'an Children\'s or Chang\'an Hospital. In addition, 100 subjects with normal FT4 and TSH levels and undergoing neonate thyroid screening were included in the normal control group. They were all Han Chinese from Shaanxi, China and consisted of 45 males and 55 females with a mean age of 5 days (4--10 days) on the day of sample collection for neonatal screening. Blood samples from the fathers and mothers of 20 patients were collected for segregation analysis. At the time of the study, the mean age of these fathers and mothers was 30.7 years (22--42 years) and 29.3 years (20--45 years), respectively. The parents of all the participants gave written informed consent in accordance with the Declaration of Helsinki. The study was approved by the Medical Ethics Committees of Xi\'an Children\'s Hospital and Chang\'an Hospital.

### DNA extraction and sequencing

Blood samples were collected from recruited patients, their family members and the control subjects and stored in EDTA tubes. Genomic DNA was extracted and analyzed as previously described ([@b24-mmr-22-01-297]).

According to the previous findings described in published literature ([@b1-mmr-22-01-297],[@b4-mmr-22-01-297]--[@b6-mmr-22-01-297]) and the retrieval results of the Human Gene Mutation Database (HGMD Professional 2016, <http://www.hgmd.cf.ac.uk/ac/index.php>), 29 causative genes (*PAX8, FOXE1, NKX2-5, TSHR, NKX2-1, DUOX2, DUOXA2, TPO, SLC26A4, FOXI1, TG, SLC5A5, IYD, SECISBP2, TSHB, IGSF1, TRHR, HESX1, LHX3, LHX4, POU1F1, PROP1, SOX3, THRB, THRA, SLC16A2, GLIS3, UBR1* and *ZNF252P*) associated with CH were selected. The recruited patients were genetically screened with a customized AmpliSeq panel (Thermo Fisher Scientific, Inc.) that included 29 CH-associated genes. The primers for the customized panel were designed with Ion AmpliSeq Designer (<https://www.ampliseq.com/browse.action>) for the inclusion of coding exons and the 20 flanking base pairs of the splice junctions surrounding the exons of the targeted genes. A total of 457 amplified amplicons were obtained at each sequencing run. Amplicon length was 125--374 bp (median 358 bp; [Table SII](#SD3-mmr-22-01-297){ref-type="supplementary-material"}). The amplicon library preparation and DNA template preparation and enrichment were conducted according to the manufacturers\' protocols. DNA sequencing was performed with an Ion Torrent PGM instrument. An Ion PGM 200 sequencing kit and Ion 316™ Chip (Thermo Fisher Scientific, Inc.) were used, according to the manufacturers\' protocols.

### Variant detection and prioritization

Raw data were processed by the Torrent Suite software (version 5.0.4; Thermo Fisher Scientific, Inc.) for the generation of sequence reads. Each read was aligned to the hg19 human reference genome for the detection of variants. Called variants were functionally annotated with Ion Reporter (<https://ionreporter.lifetechnologies.com/ir/secure/home.html>) and ANNOVAR package (<http://wannovar.wglab.org/>). Identified variants were filtered as follows: i) Synonymous variants and nonsplice variants in the intronic region were excluded; ii) variants with minor allele frequencies (MAF) of ≤0.01 or no MAF values in the dbSNP database (<http://www.ncbi.nlm.nih.gov/projects/SNP/>), 1000 Genomes Project (<http://ftp.ncbi.nih.gov/>), Exome Sequencing Project (<http://evs.gs.washington.edu/EVS/>) and the Genome Aggregation Database (gnomAD, <http://gnomad.broadinstitute.org/>) were selected; iii) variants without rs numbers in the dbSNP database were considered novel rare variants; iv) CH-associated variants reported in the published literature or by the HGMD database (HGMD Professional 2019.3) were selected even if ii) or iv) was not met; v) all selected variants were validated through Sanger sequencing with ABI3500 ×L Dx (Applied Biosystems, Thermo Fisher Scientific, Inc.); and vi) all validated novel variants were determined in the normal control by Sanger sequencing and were filtered by MAF ≤0.01. The present study was conducted on the basis of these prioritization criteria. The prioritized variants were detected in the parental samples of patients for the verification of the inheritance of variants and segregation with phenotype.

### Bioinformatics and statistical analysis

The possible functional effects of detected variants were assessed by *in silico* programs. For missense or indel variants, five *in silico* tools were used, including Polymorphism Phenotyping v2 ([http://genetics.bwh.harvard.edu/pph2/ index.shtml](http://genetics.bwh.harvard.edu/pph2/ index.shtml)), MutationTaster (<http://www.mutationtaster.org/>), Rare Exome Variant Ensemble Learner (<https://sites.google.com/site/revelgenomics/>) and Mendelian Clinically Applicable Pathogenicity (<http://bejerano.stanford.edu/MCAP/>). For the splicing variants, the deleterious effect on RNA splicing was predicted with MaxEntScan (<http://genes.mit.edu/burgelab/maxent/Xmaxentscan_scoreseq.html>), Berkeley Drosophila Genome Project ([http://www.fruitfly.org/seq_tools/ splice.html](http://www.fruitfly.org/seq_tools/ splice.html)) and NetGene2 ([http://www.cbs.dtu.dk/services/ NetGene2/](http://www.cbs.dtu.dk/services/ NetGene2/)).

The evolutionary conservation analysis was performed using the CLC Sequence Viewer 6.5.2 software (CLC bio, Qiagen AB). Protein domains and structures were obtained from UniProt and InterPor Knowledgebase ([http://www.uniprot. orssswq333 g/](http://www.uniprot. orssswq333 g/); <http://www.ebi.ac.uk/interpro/>).

The pathogenicity of each variant was assessed according to the standards described by the American College of Medical Genetics (ACMG) ([@b25-mmr-22-01-297]).

The clinical features of the two groups (such as patients with *DUOX2* mutation and patients without *DUOX2* mutation) were compared through a Mann-Whitney test for nonparametric values. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Demographic and clinical characteristics of the patients

The present study included 43 Chinese Han patients diagnosed with primary CH. The recorded demographic data and clinical features of the patients are presented in [Table I](#tI-mmr-22-01-297){ref-type="table"}: The enrolled patients consisted of 25 females and 18 males, aged 3 months to 13 years. All of the cases were from unrelated families with no histories of thyroid diseases, apart from patients 32 and 33, who were monozygotic twins. Thyroid ultrasonography suggested that 11 patients had TD, of which 6 had athyreosis, 4 had hypoplasia and 1 had ectopy. A total of 32 cases had eutopically located glands *in situ* (GIS), 18 of which had normal thyroid sizes and 14 had goiter ([Table I](#tI-mmr-22-01-297){ref-type="table"}).

### Sequencing data analysis

NGS analysis was performed on the 43 patients with CH and the result showed that the number of mapped reads for individual samples was 149,698-1,458,751 (median: 394571, n=43). The percentages of the on-target sequences in each sample all had a median of 99%, with an average base coverage depth ranging from 215.9--3× in individual samples. The average total coverages of all the targeted bases were 94.80% at 20×, 87.06% at 100× and 57.51% at 500×. Coverage was also uniform across all samples. On average, 94.8% of the called bases had a quality score of ≥Q20 ([Table SIII](#SD4-mmr-22-01-297){ref-type="supplementary-material"}).

In 25 genes (86.2%), all of the targeted amplicons were covered by 20 reads or more ([Fig. S1](#SD1-mmr-22-01-297){ref-type="supplementary-material"}). Exons that were covered less than 20× or missed by the NGS were subjected to Sanger sequencing ([Table SIV](#SD5-mmr-22-01-297){ref-type="supplementary-material"}).

### Variant detection and mutation spectrum

Following functional filtering, 47 rare nonpolymorphic variants were identified in 31 of 43 patients (71%). These variants were distributed in 9 genes, including 6 DH-associated genes (*DUOX2, TG, TPO, SLC26A4, DUOXA2* and *SLC5A5*), 1 gene associated with TD (*TSHR*) and 2 genes associated with central hypothyroidism (*PROP1* and *TRHR*, [Fig. 1A](#f1-mmr-22-01-297){ref-type="fig"}). Notably, all variants were detected in heterozygous status in patients. Various types of mutations have been detected and most of them were missense variants ([Table II](#tII-mmr-22-01-297){ref-type="table"}; [Fig. 1A](#f1-mmr-22-01-297){ref-type="fig"}). A total of 8 novel variants were identified ([Table II](#tII-mmr-22-01-297){ref-type="table"}; [Fig. S2](#SD1-mmr-22-01-297){ref-type="supplementary-material"}); these were absent in the local control samples. The 39 remaining variants had been reported in HGMD, dbSNP, gnomAD and/or 1000 human genome databases.

Of the 9 mutated genes, the gene with the highest number of variants was *DUOX2*, followed by *TG, TPO* and *TSHR* ([Fig. 1A](#f1-mmr-22-01-297){ref-type="fig"}). Twenty variants in *DUOX2* were identified in 19 cases (19/43, 44%), that is, 17 patients with GIS and 2 patients with TD ([Fig. 1B](#f1-mmr-22-01-297){ref-type="fig"}). Of these patients, 10 (10/43, 23%) carried ≥2 different heterozygous variants in *DUOX2*. A total of 6 patients carried *DUOX2* mutation(s) in association with mutation(s) in *TG* (n=4) or *SLC26A4* (n=2). The most common mutation was p.R1110Q (*DUOX2*: c.3329G\>A), which was found in 5 patients, accounting for 11% of all the cases. Of the 3 novel variants in *DUOX2*, p.T803fs was a frameshift mutation and had a potential deleterious effect on protein function and p.D137E and p.E389K were missense mutations located in the peroxidase-like domain ([Fig. S3A](#SD1-mmr-22-01-297){ref-type="supplementary-material"}).

A total of 9 variants in *TG* were identified in 8 CH patients (8/43, 18.6%), 2 of which had ≥2 *TG* variants. Apart from carrying *TG* mutation(s), 6 cases also had mutation(s) in genes associated with DH (*SLC26A4, DUOX2, DUOXA2* and *TPO*).

A total of 6 *TPO* variants were separately found in 6 patients (6/43, 14%) in heterozygous status. All but 1 patient had a *TPO* mutation in association with mutation(s) in different genes. A total of 2 novel variants, p.S309P and p.S571R, were located in a myeloperoxidase-like domain, the catalytic site of the enzyme ([Fig. S3B](#SD1-mmr-22-01-297){ref-type="supplementary-material"}).

A total of 4 *TSHR* variants were found in 2 patients and were compound heterozygotes for 2 different *TSHR* mutations. The *TSHR* variant p.R450H was a recurrent inactivating mutation ([@b26-mmr-22-01-297]) and p.C176R and p.K618 were novel. p.C176R is located in the leucine-rich repeat region of the extracellular domain and responsible for high-affinity hormone binding and p.R528S and p.K618\* are located in the cytoplasmic loops ([Fig. S3C](#SD1-mmr-22-01-297){ref-type="supplementary-material"}).

Patients with GIS had a higher tendency to be affected with mutations than patients with TD \[25/32 (78%) vs. 6/11 (54%), [Fig. 2](#f2-mmr-22-01-297){ref-type="fig"}\]. Variants in *TG, TSHR, DUOXA2, SLC5A5* and *PROP1* genes were found exclusively in patients with GIS, and 1 variant in *TRHR* was found in patients with TD. Other genes, including *DUOX2, TPO* and *SLC26A4*, were associated with either dysgenesis or GIS phenotype ([Table II](#tII-mmr-22-01-297){ref-type="table"} and [Fig. 1B](#f1-mmr-22-01-297){ref-type="fig"}). The variants detected in the 6 patients with TD (two athyreosis, two hypoplasia and one ectopy) were all located in genes associated with DH. A total of 12 patients (12/43, 28%) carried only 1 heterozygous variant and 19 cases (19/43, 44%) had ≥2 variants, 8 of which were monogenic (having mutations in the same gene) and 11 were oligogenic (having mutations in different genes, [Table III](#tIII-mmr-22-01-297){ref-type="table"}).

### Pathogenicity assessment

The pathogenicity of the detected variants was classified in accordance with ACMG standards and guidelines ([Table II](#tII-mmr-22-01-297){ref-type="table"}, [Tables SV](#SD6-mmr-22-01-297){ref-type="supplementary-material"} and [SVI](#SD7-mmr-22-01-297){ref-type="supplementary-material"}). Among the 47 variants, 25 were classified as pathogenic (P) or likely pathogenic (LP), namely, 16 in *DUOX2*, 4 in *TSHR*, 2 in *TPO*, 2 in *TG* and 1 in *DUOXA2* gene. A total of 21 variants were classified as variants of uncertain significance (VUS) and 1 variant in *TPO* was classified as likely benign. Among the 8 novel variants, 4 were classified as P (p.C176R and p.K618\* in *TSHR*, p.T803fs in *DUOX2*) or LP (p.D137E in *DUOX2*), the other were classified as VUS.

### Genotype and phenotype relationship

Through family segregation and pathogenicity assessment, 13 cases (patients 6, 11, 15,17, 16, 28, 29, 32, 33, 34, 37 and 42) were considered 'solved,' reaching a diagnosis detection rate of 30% ([Tables I](#tI-mmr-22-01-297){ref-type="table"} and [III](#tIII-mmr-22-01-297){ref-type="table"}, and [Fig. S1](#SD1-mmr-22-01-297){ref-type="supplementary-material"}). These 'solved' cases all carried at least 2 pathogenic variants in the same gene, which were of either paternal or maternal origin, but not from a single parent, following the identification of a decisive link between genotype and phenotype. A total of 18 cases (41.9%) were considered 'ambiguous' owing to the weak link between genotype and phenotype. In addition, 12 cases were considered 'unsolved' because they carried no mutations in any of the listed genes.

Among the solved cases, 8 were monogenic and 5 were oligogenic. The main pathogenic genes were *DUOX2* (n=9), *TSHR* (n=2), *DUOXA2* (n=1) and *TG* (n=1). Notably, all of the 'solved' cases were patients with GIS ([Tables I](#tI-mmr-22-01-297){ref-type="table"} and [III](#tIII-mmr-22-01-297){ref-type="table"}). Therefore, the diagnosis rate in patients with GIS patients was 40.6% (13/32; [Table III](#tIII-mmr-22-01-297){ref-type="table"}).

According to the number of variants carried, the studied cases were classified into different groups and the serum levels of TSH and FT4 were compared among these groups ([Fig. SIV](#SD1-mmr-22-01-297){ref-type="supplementary-material"}). The results showed that only the average serum TSH level of patients with TG mutation at diagnosis were significantly higher than those without *TG* mutation (49.54 µIU/ml vs. 68.71 µIU/ml, P=0.037, [Fig. S4A-b](#SD1-mmr-22-01-297){ref-type="supplementary-material"}). The average serum levels of FT4 of patients with monogenic mutation at diagnosis were higher compared with patients with oligogenic mutations, but the difference was not statistically significant (P=0.05, [Fig. S4D-c](#SD1-mmr-22-01-297){ref-type="supplementary-material"}).

Discussion
==========

To the best of our knowledge, the present study is the first in which the currently largest targeted NGS panel containing 29 known causative genes was used for the comprehensive examination of the mutation spectrum of Han Chinese CH patients. The present study found a high mutation rate (44%) in primary CH patients and most of the mutations (91.5%) were identified in genes associated with DH. In addition, mutations in genes associated with thyroid development or transcription were rarely identified. The majority of CH were caused by TD and \<20% of cases showed strong genetic predisposition ([@b1-mmr-22-01-297],[@b2-mmr-22-01-297]). However, in the patient cohort, DH (n=32) was more common than TD (n=11). This result is in agreement with the data reported in China ([@b27-mmr-22-01-297]--[@b31-mmr-22-01-297]). Given that DH is largely caused by genetic defects and considered a hereditary disease, a majority of CH cases in Chinese are hereditary and have a strong genetic origin. In the present study, mutation detection rate in CH patients with DH was 78% and the diagnosis rate in DH was 40.6%. Notably, the 6 patients with TD harbored mutations that were all associated with DH, 2 of whom had athyreosis. Patients with TD, especially those with athyreosis, are unlikely to carry variants associated with DH. However, in the present study, patients were subjected to thyroid ultrasonography rather than to whole-body nuclear magnetic resonance scanning for the examination of thyroid morphology. Thus, those examined as athyreosis could not be excluded for the likelihood of ectopy. Similarly, other studies have found variants associated with DH in patients with athyreosis ([@b30-mmr-22-01-297],[@b32-mmr-22-01-297]). In addition, 2 individual variants in genes associated with pituitary development or central CH (*PROP1* and *TRHR*) respectively were found in 1 CH patient with GIS and 1 patient with TD, and both variants co-occurred with genetic variants associated with DH. Currently, it is difficult to be sure that the genetic defects associated with DH contribute to the development of TD or the potential effect of variants associated with pituitary development on primary CH. However, the findings of the present study validated the complicated pathological mechanism of CH. Thus, studies on the genetic origin of TD or DH diseases should not be limited to well-known causative genes ([@b4-mmr-22-01-297],[@b33-mmr-22-01-297]).

In the present study, *DUOX2* was the most common genetic alteration identified in CH patients. The detection rate of *DUOX2* mutation in the studied CH cohort and the GIS patients were 44% (19/43) and 53.1% (17/32), respectively, most of which carried ≥2 *DUOX2* mutations. This finding was in accordance with those previously reported showing that *DUOX2* mutation is the leading genetic cause of CH in Asian populations, including other Han Chinese, Japanese and Koreans; the detection rate of *DUOX2* in patients from Asian populations is 16.5--3% and ≤83% in patients with DH ([@b27-mmr-22-01-297],[@b29-mmr-22-01-297],[@b31-mmr-22-01-297],[@b34-mmr-22-01-297]--[@b40-mmr-22-01-297]). *TG* and *TPO* mutations were also commonly found in the studied cohort. However, a majority of these mutations were either separately presented at a heterozygous status or detected with mutations in different genes. Thus, *TG* and *TPO* may act as contributing genetic factors apart from being the main genetic causes of CH in the studied cohort. In some Caucasian cohorts, *TPO* has been identified as the main genetic cause of CH ([@b41-mmr-22-01-297]--[@b43-mmr-22-01-297]). In addition, loss-of-function (LOF) mutations in the TSH receptor (*TSHR*) gene were identified as the most frequent cause of TSH resistance, leading to a wide spectrum of phenotypes ranging from severe CH to mild euthyroid hyperthyrotropinemia ([@b26-mmr-22-01-297],[@b44-mmr-22-01-297]). In the present study, 2 patients with CH who were compound heterozygotes for 2 different *TSHR* mutations (1 for p.R528S and p.R450H and 1 for p.C176R and p.K618\*) demonstrated mild clinical phenotypes (5 pmol/l≤FT4\<10 pmol/l) ([@b45-mmr-22-01-297]). This finding is in agreement with previous studies reporting that compound heterozygotes of less severe LOF mutations are usually associated with mild/borderline forms of hypothyroidism, wherein an appropriate increase in TSH serum levels can compensate for the reduced sensitivity of the thyroid (partially or fully compensated TSH resistance) ([@b26-mmr-22-01-297],[@b44-mmr-22-01-297],[@b46-mmr-22-01-297],[@b47-mmr-22-01-297]). Previously reported clinical cases with *TSHR* mutations are always characterized by normal-sized or hypoplastic thyroid gland ([@b26-mmr-22-01-297],[@b46-mmr-22-01-297],[@b47-mmr-22-01-297]). However, in the present study, patient 37 suffered from goiter. In addition to *TSHR* mutations, this patient also carried a heterozygous variant in *TPO*, which may be the reason leading to this phenotypic variability.

At present, patients with CH caused by genetic defects are considered to be inherited in a monogenic manner. However, phenotypic variability observed in patients with same mutations indicated the influence of other factors, such as genetic heterogeneity ([@b15-mmr-22-01-297],[@b34-mmr-22-01-297],[@b42-mmr-22-01-297],[@b43-mmr-22-01-297],[@b48-mmr-22-01-297]--[@b50-mmr-22-01-297]). The present study found a high percentage (25.6%) of involvement of oligogenic mutations in studied cases, which is similar to that of previous studies simultaneously assessing multiple genes ([@b15-mmr-22-01-297],[@b30-mmr-22-01-297]--[@b32-mmr-22-01-297]). These studies reported frequent oligogenic involvement in CH, with oligogenic mutations in 20--43.5% of patients with CH and GIS and/or patients with TD in different ethnic populations. In addition, among the 13 'solved' cases through family segregation and pathogenicity assessment, 5 cases carried oligogenic mutations and none of the mutations was inherited from a single parent. These findings suggested that, not only monogenic inheritance, but also digenic or oligogenic inheritance is involved in the pathogenesis of CH. However, available evidence is insufficient for oligogenic inheritance verification, and protein-protein interaction for the two proteins or genes, pedigree data, animal models or very specific functional experiments are key factors ([@b18-mmr-22-01-297]). At present, only 1 study performed in mice demonstrated a multigenic origin of CH with TD ([@b51-mmr-22-01-297]). Therefore, further studies are required for the validation of the role and mechanism of oligogenicity in CH pathogenesis.

The data of the present study were compared with those of several similar studies that analyzed the mutation spectrum of CH patients in China by using NGS ([@b29-mmr-22-01-297]--[@b31-mmr-22-01-297]). The investigated patients in the present study were from northwestern China (Shaanxi Province), whereas those in the previous studies were mainly from southern China (Jiangsu and Guangxi Provinces). The general mutation profiles of patients with CH demonstrated by these studies were similar. For example, the total mutation rate in CH patients reported in these studies was relatively high, i.e., 48.5% ([@b29-mmr-22-01-297]), 65.09% ([@b31-mmr-22-01-297]), 80.9% ([@b30-mmr-22-01-297]) and 72% (the present study). *DUOX2* mutations were the prevalent genetic alterations in these studies, with a mutation rate of 31.8% ([@b29-mmr-22-01-297]), 31.3% ([@b31-mmr-22-01-297]), 60% ([@b30-mmr-22-01-297]) and 44% (the present study). Therefore, the region (or population)-specific characteristics in patients with CH from these studies could not be ascertained. However, some different findings in the present study were observed. For example, *DUOX2* and *TG* mutations were the first and second most common mutations detected in all these studies. However, the third and fourth most common genetic mutations were different. In the present study, the third and fourth most common genetic mutation were *TPO* and *TSHR* mutations, respectively. in addition, the third and fourth most common genetic mutations reported by Long *et al* ([@b31-mmr-22-01-297]) were *TSHR* and *GNAS* mutations, respectively and those by Sun *et al* ([@b30-mmr-22-01-297]) were *TPO* and *DUOXA1* mutations, respectively. These discrepancies may be caused by the relatively small sample size, sampling criteria and/or different targeted genes determined.

Several limitations were observed in the present study. The sample size was relatively small, and most patients were too young to exhibit clinical phenotypes. Thus, determining the clinical significance of the detected mutations was difficult. Pedigree analysis was not performed in all the cases carrying mutations and evidence to support the pathogenicity of detected variants was insufficient. The diagnosis detection rate in the present study would be \>30% were these requirements met. Finally, *in vitro* functional study of novel variants identified in the current study should be carried out.

In conclusion, using the currently largest targeted NGS panel containing 29 known genes, the mutation spectrum of 43 Han Chinese patients with CH was comprehensively determined. The main findings showed that DH other than TD is the common cause of CH in Chinese populations and genetic alterations associated with thyroid hormone biosynthesis, especially *DUOX2* mutations, are the main genetic causes of CH. In addition, a high percentage of involvement of oligogenic mutation in the studied cases confirmed the potential role of oligogenicity or non-Mendelian inheritance in CH pathogenesis.
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###### 

Clinical Information, detected variants, and results of family segregation analysis of studied patients with CH.

                                                                         Screening   Neonatal period                                                                                                                                                                           
  -------- ----------- ------ ----------------------- ------------------ ----------- ----------------- ------- ----- ------------------------------------------------------------------------------------------------------------ ---------------------- --------------------- -----------
  1        7y10m, F    3050   32+5                    Hypoplasia         14.1        39d               15      6.7   *SLC5A5* p.Q639\* (CT)                                                                                       NA                     NA                    Ambiguous
  2        3y9m, F     3000   Full term               Athyreosis (53d)   35.4        69d               \>100   1.2   *TPO* p.R361L (GT)                                                                                           GG                     GT                    Ambiguous
  3        1y1m, M     4000   Full term               Hypoplasia         20.3        76d               14.8    6.7   *SLC26A4* p.A434T (GA), *TRHR* p.I168M (TG)                                                                  NA                     NA                    Ambiguous
  4        1y3m, F     3400   Full term               Normal             28          25d               35.2    4.9   *DUOX2* p.A1206T (GA)                                                                                        GA                     GG                    Ambiguous
  5        3m, M       3600   41                      Normal             21.2        20d               92.8    3.6   *DUOX2* p.E879K (GA)                                                                                         NA                     NA                    Ambiguous
  6        4y6m, M     3300   Full term               Goiter             29          74d               \>100   2.6   *DUOX2* p.K530\* (AT), *DUOX2* p.R1110Q (GA)                                                                 AA;GA                  AT;GG                 Solved
  7        5m, M       3800   Full term               Hypoplasia         9.61        43d               20      5.7   *DUOX2* p.T803fs (c.2406_2407insCCTG)                                                                        NA                     NA                    Ambiguous
  8        4y, F       4000   40+5                    Athyreosis (1y)    20          58d               36.5    4.8                                                                                                                NA                     NA                    Unsolved
  9        7m, M       2750   36+5                    Goiter             20.5        30d               30.2    5.1   *DUOX2* p.R434\* (CT)                                                                                        CC                     CT                    Ambiguous
  10       8m, F       3000   33+2                    Normal             7.5         56d               16.9    6.6                                                                                                                NA                     NA                    Unsolved
  11       1y9m, M     3800   Full term               Normal             19          60d               25      6.2   *TSHR* p.R528S (CA), *TSHR* p.R450H (GA)                                                                     CC;GA                  CA;GG                 Solved
  12       3y, F       3400   Full term (Suspected)   Ectopy             \>100       33d               \>100   0.8   *DUOX2* p.V779M (GA), *SLC26A4* p.Y578H (TC)                                                                 GG;TC                  GA;TT                 Ambiguous
  13       1y3m, F     3200   Full term               Normal             15.3        63d               20      6.4                                                                                                                NA                     NA                    Unsolved
  14       2y9m, M     3400   Full term               Goiter             24.2        33d               32.8    5                                                                                                                  NA                     NA                    Unsolved
  15       2y4m, M     3900   Full term               Normal             21          57d               28      5.3   *DUOXA2* p.R94C (CT), *DUOXA2* p.Y246\* (CG), TG p.N212S (AG)                                                CC;CG; AG              CT;CC, AA             Solved
  16       11m10d, M   3200   Full term               Goiter             100         62d               \>100   1.1     *DUOX2* p.R376W (CT), *DUOX2* p.R434_S440del (del/wt), *DUOX2* p.R1110Q (GA)                               CT;del/wt;GG           CC;wt/wt;GA           Solved
  17       11m, M      3100   Full term               Normal             14.6        65d               19.54   6.5   *DUOX2* p.R885L (GT), *DUOX2* p.Y1415C (AG)                                                                  GT;AA                  GG; AG                Solved
  18       2y2m, F     2600   Full term               Normal             77          67d               77      4.1   *TG* p.R2585W (CT), *DUOX2* p.A1206T (GA)                                                                    NA                     NA                    Ambiguous
  19       1y, M       3050   full term               Hypoplasia         18          32d               21      6.3                                                                                                                NA                     NA                    Unsolved
  20       9y, F       3500   Full term               Normal             \>100       20d               \>100   0.7   *TPO* p.E757\* (dupT/wt), *TG* p.I1931V (AG), *DUOX2* p.K530\* (AT)                                          wt/wt;AA; AA           dupT/wt; AG;AT        Ambiguous
  21       9y, F       3000   Full term               Athyreosis         \>100       30d               \>100   0.5                                                                                                                NA                     NA                    Unsolved
  22       4y7m, M     3500   Full term               Normal             31          49d               40      4.8                                                                                                                NA                     NA                    Unsolved
  23       3y, F       3000   Full term               Goiter             40          74d               40      4.8   *TG* p.R896Q (GA)                                                                                            NA                     NA                    Ambiguous
  24       1y6m, M     3500   Full term               Normal             19          61d               58.21   4.5   *TPO* p.R846W (CT), *TG* p.E955fs (c.2864delA), *TG* p.I1931V (AG), *TG* p.L2282fs (c.6840_6843delTTGT)      CT;del/wt; AG, wt/wt   CC;wt/wt;AA, del/wt   Solved
  25       8m, F       2400   Full term               Normal             58.21       32d               \>100   6.7   *TG* p.I2394M (CG)                                                                                           CC                     CG                    Ambiguous
  26       13y, F      3900   Full term               Goiter             16.5        28d               \>100   6.5                                                                                                                NA                     NA                    Unsolved
  27       2y6m, F     3100   38+1                    Goiter             25.6        35d               35      6.3                                                                                                                NA                     NA                    Unsolved
  28       2y, F       3000   40                      Goiter             26          72d               46.5    4.7   *TG* p.V1738I (GA), *TG* p.S1912N (GA), *DUOX2* p.D137E (CA), *DUOX2* p.R432H (GA), *DUOXA2* p.Y246\* (CG)   GA;GA; CA;GG; CG       GG;GG; CC;GA; CC      Solved
  29       3y3m, F     3300   Full term               Goiter             \>100       58d               \>100   2     *DUOX2* p.R625\* (CT), *DUOX2* p.R1110Q (GA)                                                                 CC;GA                  CT;GG                 Solved
  30       6y, M       3000   37                      Goiter             18          58d               20      6.4   *TPO* p.S571R (CG), *PROP1* p.G51V (GT)                                                                      CG;GG                  CC;GT                 Ambiguous
  31       5y6m, F     2900   40                      Normal             20.6        53d               18.3    6.5                                                                                                                NA                     NA                    Unsolved
  32       5y11m, M    2200   37+1                    Normal             20          65d               18.2    6.5   *DUOX2* p.F591S (TC), *DUOX2* p.E879K (GA), *DUOX2* p.G1521\* (GT)                                           TC;GA; GG              TT;GG; GT             Solved
  33       5y11m, M    2600   37+1                    Normal             22.5        65d               20.3    6.3   *DUOX2* p.F591S (TC), *DUOX2* p.E879K (GA), *DUOX2* p.G1521\* (GT)                                           TC;GA; GG              TT;GG; GT             Solved
  34       1y4m, F     3300   40+1                    Goiter             16.5        71d               15.8    6.7   *DUOX2* p.R885L (GT), *DUOX2* p.R1110Q (GA)                                                                  GG;GA                  GT;GG                 Solved
  35       2y10m, F    3650   Full term               Athyreosis         \>100       52d               \>100   0.8                                                                                                                NA                     NA                    Unsolved
  36       1y11m, F    3400   39+4                    Athyreosis         \>100       47d               \>100   0.9                                                                                                                NA                     NA                    Unsolved
  37       1y, M       3750   Full term               Goiter             35.1        78d               35      4.9   *TSHR* p.C176R (TC), *TSHR* p.K618\* (AT), *TPO* p.P883S (CT)                                                TT;AT; CC              TC;AA; CT             Solved
  38       1y2m, F     3300   Full term               Athyreosis         46.1        64d               \>100   1.9   *TPO* p.P883S (CT), *GLIS3* p.A753V (CT)                                                                     NA                     NA                    Ambiguous
  39       9m, F       3600   39+2                    Normal             \>100       47d               \>100   2.1   *DUOX2* p.E389K (GA)                                                                                         NA                     NA                    Ambiguous
  40       8m, F       1900   38                      Normal             15          33d               15      7.1   *TPO* p.S309P (TC)                                                                                           NA                     NA                    Ambiguous
  41       4y9m, F     2800   Full term               Normal             21          90d               18      6.5   *DUOX2* p.G624fs (c.1871delG)                                                                                NA                     NA                    Ambiguous
  42       1y3m, F     2700   41+2                    Goiter             \>100       68d               \>100   0.7   *SLC26A4* p.Y78H (TC), *DUOX2* p.R885L (GT), *DUOX2* p.R1110Q (GA)                                           TT, GG, GA             TC, GT, GG            Solved
  43       1y1m, M     3800   40                      Goiter             \>100       74d               \>100   0.6   *TPO* p.R846W (CT), *TG* p.R896Q (GA), c.3693+1G\>T (GT) *DUOX2* p.V407F (GT), *DUOX2*                       NA                     NA                    Ambiguous
  Normal                      \<10                                       0.27--3.2   12-22                                                                                                                                                                                     

the age of each patient was calculated based on the date of birth and sample collection. CH, congenital hypothyroidism; m, month; d, day; y, year; F, female; M, male; TSH, thyroid-stimulating hormone; FT4, free tetraiodothyronine; \*, a nonsense mutation which caused a premature termination in gene product; NA, data not available.

###### 

Potential pathological variants detected in the present study.

                                                       Minor allele frequency                                                                                             
  ----------- ------------- -------------- ----------- ------------------------ ------- ------------ -------- ----------------------------------------------------------- -----
  *TSHR*      p.C176R       c.526T\>C      6                                    0.012   0            0        Novel                                                       LP
  *TSHR*      p.R450H       c.1349G\>A     10          rs189261858              0.012   0.002597     0.0049   Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    P
  *TSHR*      p.R528S       c.1582C\>A     10                                   0.012   0            0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    LP
  *TSHR*      p.K618\*      c.1852A\>T     10                                   0.012   0            0        Novel                                                       P
  *DUOX2*     p.D137E       c.411C\>A      5                                    0.012   0            0        Novel                                                       LP
  *DUOX2*     p.R376W       c.1126C\>T     10          rs119472029              0.012   0            0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    LP
  *DUOX2*     p.E389K       c.1165G\>A     11                                   0.012   0            0        Novel                                                       VUS
  *DUOX2*     p.V407F       c.1219G\>T     11                                   0.012   0            0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    VUS
  *DUOX2*     p.R432H       c.1295G\>A     12          rs530736554              0.012   0.0004769    0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    LP
  *DUOX2*     p.R434\*      c.1300C\>T     12          rs119472026              0.012   0.000116     0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    P
  *DUOX2*     p.R434\_      c.1300_1320                                                                                                                                   
              S440del       delCG          12                                   0.012   0            0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    P
                            AGATATGGGG                                                                                                                                    
                            CTGCCCAGC                                                                                                                                     
  *DUOX2*     p.K530\*      c.1588A\>T     14          rs180671269              0.024   0.009274     0.0095   Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    P
  *DUOX2*     p.F591S       c.1772T\>C     15                                   0.024   0.00007081   0        Known^[c](#tfn5-mmr-22-01-297){ref-type="table-fn"}^        VUS
  *DUOX2*     p.G624fs      c.1871delG     16          rs769258094              0.012   0.0004638    0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    P
  *DUOX2*     p.R625\*      c.1873C\>T     16          rs770083296              0.012   0            0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    P
  *DUOX2*     p.V779M       c.2335G\>A     19          rs145061993              0.012   0.004094     0.0049   Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM?   VUS
  *DUOX2*     p.T803fs      c.2406_2407    19                                   0.012   0            0        Novel                                                       P
                            insCCTG                                                                                                                                       
  *DUOX2*     p.E879K       c.2635G\>A     20          rs774556391              0.036   0.000954     0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    P
  *DUOX2*     p.R885L       c.2654G\>T     20          rs181461079              0.036   0.005777     0.0049   Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM?   LP
  *DUOX2*     p.R1110Q      c.3329G\>A     25          rs368488511              0.06    0.002597     0.0049   Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    P
  *DUOX2*     p.A1206T      c.3616G\>A     28          rs762588205              0.024   0.0001739    0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM?   LP
  *DUOX2*     IVS28+1G\>T   c.3693+1G\>T   intron 28   rs200717240              0.012   0.001537     0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    P
  *DUOX2*     p.Y1415C      c.4244A\>G     32          rs757012152              0.012   0.00008334   0        Known^[c](#tfn5-mmr-22-01-297){ref-type="table-fn"}^        LP
  *DUOX2*     p.G1521\*     c.4561G\>T     34          rs765781255              0.024   0.001044     0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^        LP
  *DUOXA2*    p.R94C        c.280C\>T      3                                    0.012   0            0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    VUS
  *DUOXA2*    p.Y246\*      c.738C\>G      5           rs4774518                0.024   0.00188      0.0291   Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    P
  *SLC5A5*    p.Q639\*      c.1915C\>T     15                                   0.012   0            0        Novel                                                       VUS
  *TPO*       p.S309P       c.925T\>C      8                                    0.012   0            0        Novel                                                       VUS
  *TPO*       p.R361L       c.1082G\>T     8           rs201781919              0.012   0.009273     0.0194   Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    VUS
  *TPO*       p.S571R       c.1713C\>G     10                                   0.012   0            0        Novel                                                       VUS
  *TPO*       p.E757\*      c.2268dupT     13          rs770781635              0.012   0.00159      0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    P
  *TPO*       p.R846W       c.2536C\>T     15          rs28913014               0.024   0.00159      0.0049   Known^[c](#tfn5-mmr-22-01-297){ref-type="table-fn"}^        VUS
  *TPO*       p.P883S       c.2647C\>T     16          rs190968346              0.024   0.005409     0.0146   Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    LB
  *PROP1*     p.G51V        c.152G\>T      2           rs2233783                0.012   0.002151     0        Known^[c](#tfn5-mmr-22-01-297){ref-type="table-fn"}^        VUS
  *SLC26A4*   p.Y78H        c.232T\>C      3           rs760794201              0.012   0            0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    VUS
  *SLC26A4*   p.A434T       c.1300G\>A     11          rs757552791              0.012   0            0        Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    VUS
  *SLC26A4*   p.Y578H       c.1732T\>C     16          rs781728302              0.012   0            0        Known^[c](#tfn5-mmr-22-01-297){ref-type="table-fn"}^        VUS
  *TRHR*      p.I168M       c.504T\>G      1           rs13306060               0.012   0.00212      0.0049   Known^[c](#tfn5-mmr-22-01-297){ref-type="table-fn"}^        VUS
  *TG*        p.N212S       c.635A\>G      5           rs187737243              0.012   0.002122     0        Known^[c](#tfn5-mmr-22-01-297){ref-type="table-fn"}^        VUS
  *TG*        p.R896Q       c.2687G\>A     10          rs374707675              0.024   0.0007431    0.0049   Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM    VUS
  *TG*        p.E955fs      c.2864delA     11          rs767858769              0.012   0.00005798   0        Known^[c](#tfn5-mmr-22-01-297){ref-type="table-fn"}^        P
  *TG*        p.V1738I      c.5212G\>A     26          rs115053637              0.012   0.001325     0.0097   Known^[c](#tfn5-mmr-22-01-297){ref-type="table-fn"}^        VUS
  *TG*        p.S1912N      c.5735G\>A     31          rs762807254              0.012   0            0        Known^[c](#tfn5-mmr-22-01-297){ref-type="table-fn"}^        VUS
  *TG*        p.I1931V      c.5791A\>G     31          rs115877910              0.024   0.002391     0.0146   Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM?   VUS
  *TG*        p.L2282fs     c.6840_6843    39          rs774153375              0.012   0            0        Known^[c](#tfn5-mmr-22-01-297){ref-type="table-fn"}^        P
                            delTTGT                                                                                                                                       
  *TG*        p.I2394M      c.7182C\>G     41                                   0.012   0.00005798   0        Known^[c](#tfn5-mmr-22-01-297){ref-type="table-fn"}^        VUS
  *TG*        p.R2585W      c.7753C\>T     44          rs114211101              0.012   0.005379     0.0049   Known^[d](#tfn6-mmr-22-01-297){ref-type="table-fn"}^, DM?   VUS

There were a pair of twins in the studied patients, therefore, when calculating variant frequency, the total number of patients were counted as 42

status evaluated based on whether variants are reported in public databases or published literature.

variants were reported in public population databases, such as dbSNP, ExAc, or 1000 Genomes Project, but without phenotypic data and pathological assessment

variants were reported in the published literature as well as HGMD database (HGMD Professional 2019.3); DM, disease-causing mutation; DM?, a possible disease-causing mutation; DFP, disease-associated polymorphism with supporting functional evidence; fs, frameshift; \*, a nonsense mutation which caused a premature termination in gene product; NA, data not available; P, pathogenic; LP, likely pathogenic; VUS, variants of uncertain significance; LB, likely benign.

###### 

Mutation spectrum of 'solved' and 'ambiguous' cases with CH.

  Solved (n=13), all were CH with GIS                                                                                                                                                                    
  ------------------------------------- ------------------------ ------------------------ ----------- ------------------------ ----------- ------------------------ ----------- ------------------------ ------------------------
  *TSHR*                                2                        1                        *TSHR*      2                        *TPO*       1                                                             1
  *DUOX2*                               2                        4                        *DUOXA2*    2                        *TG*        1                                                             1
  *DUOX2*                               3                        3                        *DUOX2*     2                        *SLC26A4*   1                                                             1
                                                                                          *DUOX2*     2                        *TG*        2                        *DUOXA2*    1                        1
                                                                                          *TG*        3                        *TPO*       1                                                             1
                                                                                                                                                                                                         
  **Ambiguous (n=18)**                                                                                                                                                                                   
                                                                                                                                                                                                         
  **Monogenic(n=12)**                   **Oligogenic (n=6)**                                                                                                                                             
                                                                                                                                                                                                         
  **Gene**                              **Number of variants**   **Number of patients**   **Gene1**   **Number of variants**   **Gene2**   **Number of variants**   **Gene3**   **Number of variants**   **Number of patients**
                                                                                                                                                                                                         
  *DUOX2*                               1                        6                        *SLC26A4*   1                        *TRH1*      1                                                             1
  *TG*                                  1                        2                        *DUOX2*     1                        *SLC26A4*   1                                                             1
  *TPO*                                 1                        3                        *DUOX2*     1                        *TG*        1                                                             1
  *SLC5A5*                              1                        1                        *DUOX2*     1                        *TG*        1                        *TPO*       1                        1
                                                                                          *DUOX2*     2                        *TG*        1                        *TPO*       1                        1
                                                                                          *TPO*       1                        *PROP1*     1                                                             1

CH, congenital hypothyroidism.
